Vanguard Global Advisers
KRYS icon

Vanguard Global Advisers’s Krystal Biotech KRYS Stock Holding History

Vanguard Global Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.37M Buy
11,759
+483
+4% +$144K ﹤0.01% 846
2026
Q1 		$2.91M Buy
+11,276
New +$3M ﹤0.01% 981

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Global Advisers's KRYS Position: Q2 2026 in Review

Vanguard Global Advisers increased its Krystal Biotech (KRYS) stake by 4.3% in Q2 2026, buying an estimated $144K and bringing the position to 11,759 shares worth $4.37M. The position accounts for ﹤0.01% of the portfolio, ranked #846.

Vanguard Global Advisers first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 417 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Vanguard Global Advisers held 11,759 shares of Krystal Biotech worth $4.37M as of Q2 2026.
  • Vanguard Global Advisers bought 483 Krystal Biotech shares in Q2 2026, an estimated $144K.
  • Krystal Biotech made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #846 holding.
  • Vanguard Global Advisers first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 417 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.